Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

INTRODUCTION: The potential of oncogene-driven targeted therapy is perhaps most fully realized in non-small cell lung cancer (NSCLC), given the number of genomic targets and approved matched therapies. However, invasive tissue biopsy at the time of each disease progression may not be possible and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Villaflor, Victoria, Won, Brian, Nagy, Rebecca, Banks, Kimberly, Lanman, Richard B., Talasaz, AmirAli, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341844/
https://www.ncbi.nlm.nih.gov/pubmed/27602770
http://dx.doi.org/10.18632/oncotarget.11801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341844/
https://www.ncbi.nlm.nih.gov/pubmed/27602770
http://dx.doi.org/10.18632/oncotarget.11801

Ejemplares similares